SCHEMBL635132

SCHEMBL635132

COC(=O)c1sccc1NCc1ccnc2[nH]ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 9/20 0.47
MAPK8 P45983 8/20 0.47
MAPK9 P45984 6/20 0.47
RAF1 P04049 1/20 0.45
LCK P06239 1/20 0.45
RET P07949 1/20 0.45
CYP3A4 P08684 1/20 0.45
KIT P10721 1/20 0.45
KDR P35968 1/20 0.45
MAP3K20 Q9NYL2 1/20 0.45
RIPK3 Q9Y572 1/20 0.45
NUDT1 P36639 1/20 0.44
MAPK1 P28482 2/20 0.43
HSD17B10 Q99714 1/20 0.43
HPGD P15428 3/20 0.42
PTK2 Q05397 1/20 0.42
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3733006 0.82 MAPK10 (0.65) MAPK10MAPK8MAPK9RAF1LCK
SCHEMBL19390359 0.80 KDR (0.40) MAPK10MAPK8MAPK9RAF1LCK
SCHEMBL633661 0.79 KDR (0.60) RAF1LCKRETCYP3A4KIT
SCHEMBL633813 0.79 KDR (0.75) RAF1LCKRETCYP3A4KIT
SCHEMBL1230817 0.74 TTBK1 (0.54) NPC1
SCHEMBL633821 0.73 KIT (0.57) RAF1LCKRETCYP3A4KIT
SCHEMBL27686227 0.71 NUDT1 (0.41) MAPK8RETCYP3A4KDRNUDT1
SCHEMBL14416608 0.70 NUDT1 (0.52) MAPK8RETKDRNUDT1PTK2
SCHEMBL4974267 0.70 NUDT1 (0.49) NUDT1PTK2
SCHEMBL9410725 0.69 NPC1 (0.59) MAPK10MAPK8MAPK9MAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7524859-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2009-04-28 US disclosed
CN-100471841-C (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2009-03-25 CN disclosed
CN-101087782-A (2-carboxamido)(3-amino) thiophene compounds OSI PHARM INC (US) 2007-12-12 CN disclosed
EP-1590328-A4 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2007-09-19 EP disclosed
EP-1807419-A1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed
US-20060247275-A1 (2-carboxamido)(3-amino)thiophene compounds CREW ANDREW P 2006-11-02 US disclosed
US-7101893-B2 (2-Carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2006-09-05 US disclosed
WO-2006047574-A1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2006-05-04 WO disclosed
CN-1723200-A (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2006-01-18 CN disclosed
EP-1590328-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2005-11-02 EP disclosed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US disclosed
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds CREW ANDREW P (US) 2005-09-01 US disclosed
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds OSI PHARMACEUTICALS, INC. 2005-07-14 US disclosed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US disclosed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds ABL1, NAT1, KRAS MAPK10 1195/4885MAPK8 2684/4885MAPK9 1399/4885
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds AADAC, PAM, TPMT MAPK10 2973/4885MAPK8 3158/4885MAPK9 3029/4885
US-20060247275-A1 (2-carboxamido)(3-amino)thiophene compounds PCNA, MKI67, MYC MAPK10 2699/4885MAPK8 2693/4885MAPK9 3267/4885
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds PCNA, MKI67, TPMT MAPK10 970/4885MAPK8 1531/4885MAPK9 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.